Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the
epidermal growth factor receptor (EGFR), and both are widely used in combination with …

Background: KRAS mutations have been extensively investigated as predictive biomarkers
for treatment of advanced colorectal cancer with the anti–epidermal growth factor receptor …

Background Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the
standard of care for advanced biliary cancers. We investigated the addition of cetuximab to …

Purpose To assess the effects of cetuximab plus chemotherapy as first-line treatment for
unresectable colorectal liver metastases (CLMs). Patients and Methods After resection of …

The development of molecularly targeted anticancer agents relies on large panels of tumour-
specific preclinical models closely recapitulating the molecular heterogeneity observed in …

KRAS mutations are the most common oncogenic event in colorectal cancer (CRC)
progression and their occurrence is associated with lack of response to anti epidermal …

Simple Summary Metastatic colorectal cancer (mCRC) has high incidence and mortality.
Nevertheless, innovative biomarkers have been developed for predicting the response to …

Background The epidermal growth factor receptor (EGFR) is a validated therapeutic target in
non-small cell lung cancer (NSCLC). However, current single agent receptor targeting does …

Treatment of metastatic colorectal cancer (mCRC) involves the use of active cytotoxic drugs
(irinotecan, oxaliplatin, 5-fluorouracil [5-FU], and capecitabine) and biological agents …

Accurate prediction of the clinical pharmacokinetics of new therapeutic entities facilitates
decision making during drug discovery, and increases the probability of success for early …